GC WellBeing Q1 Operating Profit Up, Net Loss Due to Derivative Loss

Consolidated Q1 2026 revenue KRW 49.1B (YoY +41.3%), operating profit KRW 4.8B (YoY +75.5%)
Consolidated net loss KRW 3.0B (vs net profit KRW 5.1B in Q1 2025): derivative valuation loss KRW 6.1B
Standalone operating profit KRW 5.0B (YoY +81%), net loss KRW 1.5B
EPS (consolidated) -KRW 172, (standalone) -KRW 82
Major shareholder changed from Green Cross Corp. to Green Cross Holdings (34.47% stake)
KRW 20B convertible bond issued (conversion price KRW 9,478), related derivative loss KRW 6.1B
Lienex IV phase 3 clinical trial completed (Mar 24, 2026) for liver function improvement
New product GC WellBeing Glymeta injection received approval (Mar 2026), launch preparation underway
Consolidated debt ratio 117.8% (prior year 97.2%), standalone 104.7% (prior year 89.5%)
Dividend payable KRW 2.5B, no share buyback/cancellation plans